efficacy of Oxcarbazepine and Phenytoin in control of epilepsy in the elderly

Comparison of efficacy and side-effects of Phenytoin versus Oxcarbazepine in secondary generalized epilepsy in the elderly

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT201202068943N1

Enrollment

142

Registered

2012-03-17

Start date

2010-11-26

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: epilepsy. Condition 2: epilepsy. Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures

Interventions

Intervention 1: For the group A were administered phenytoin capsule 100mg ( >70 y/o 100mg BID & 70 y/o,BID &70 y/o 100mg BID & 70 y/o,BID &<70y/o, TDS) was administered.the course of treatment was 6mo

Eligibility

Sex/Gender

All

Age

65 Years to 87 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age greater than 65 y/o; Not having acute treatable cause; Having secondary generalized epilepsy according to history and Exclusion criteria: Previous history of reaction to phenytin or Oxcarbazepine; Having other causes except cerebrovascular disease as primary cause of epilepsy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Dizziness. Timepoint: at onset,after 2 weeks,1 month, 2 months,4 months and 6 months. Method of measurement: History and physical examination.;Nausea and vomiting. Timepoint: at onset,after 2 weeks,1 month, 2 months,4 months and 6 months. Method of measurement: History and physical examination.;Ataxia. Timepoint: at onset,after 2 weeks,1 month, 2 months,4 months and 6 months. Method of measurement: History and physical examination.;Somnolence. Timepoint: at onset,after 2 weeks,1 month, 2 months,4 months and 6 months. Method of measurement: History and physical examination.;Lethargy. Timepoint: at onset,after 2 weeks,1 month, 2 months,4 months and 6 months. Method of measurement: History and physical examination.;Skin reaction. Timepoint: at onset,after 2 weeks,1 month, 2 months,4 months and 6 months. Method of measurement: History and physical examination.;Gingival hyperplasia. Timepoint: at onset,after 2 weeks,1 month, 2 months,4 months and 6 months. Method of measurement: History and physical examination.;Seizure symptoms. Timepoint: at onset,after 2 weeks,1 month, 2 months,4 months and 6 months. Method of measurement: History and physical examination.	—

Measure

Time frame

Dizziness. Timepoint: at onset,after 2 weeks,1 month, 2 months,4 months and 6 months. Method of measurement: History and physical examination.;Nausea and vomiting. Timepoint: at onset,after 2 weeks,1 month, 2 months,4 months and 6 months. Method of measurement: History and physical examination.;Ataxia. Timepoint: at onset,after 2 weeks,1 month, 2 months,4 months and 6 months. Method of measurement: History and physical examination.;Somnolence. Timepoint: at onset,after 2 weeks,1 month, 2 months,4 months and 6 months. Method of measurement: History and physical examination.;Lethargy. Timepoint: at onset,after 2 weeks,1 month, 2 months,4 months and 6 months. Method of measurement: History and physical examination.;Skin reaction. Timepoint: at onset,after 2 weeks,1 month, 2 months,4 months and 6 months. Method of measurement: History and physical examination.;Gingival hyperplasia. Timepoint: at onset,after 2 weeks,1 month, 2 months,4 months and 6 months. Method of measurement: History and physical examination.;Seizure symptoms. Timepoint: at onset,after 2 weeks,1 month, 2 months,4 months and 6 months. Method of measurement: History and physical examination.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehran Keshavarzi

Medical Science Facaulty

Keshavarzi.m@ajums.ac.ir+98 61 1373 8302

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026